Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1096 | 969 | 1289 | 839 | 1603 | - |
Fund Return | 9.55% | -3.14% | 28.93% | -5.67% | 9.9% | - |
Place in category | 56 | 269 | 6 | 365 | 31 | - |
% in Category | 10 | 68 | 1 | 92 | 8 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
DNCA Invest Eurose Class I shares E | 2.51B | 3.52 | 3.42 | 3.07 | ||
DNCA Invest Eurose Class AD shares | 2.51B | 2.90 | 2.68 | 2.33 | ||
DNCA Invest Eurose Class A shares | 2.51B | 2.90 | 2.69 | 2.33 | ||
DNCA Invest Europe Growth Class A s | 891.28M | -1.14 | -5.84 | 7.82 | ||
DNCA Invest Europe Growth Class B s | 891.28M | -1.47 | -6.21 | 7.42 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
DNCA Invest Europe Growth Class A s | 891.28M | -1.14 | -5.84 | 7.82 | ||
DNCA Invest Europe Growth Class B s | 891.28M | -1.47 | -6.21 | 7.42 | ||
DNCA Invest Europe Growth Class F s | 891.28M | -0.11 | -4.69 | 8.97 | ||
DNCA Invest Europe Growth Class I s | 891.28M | -0.28 | -4.88 | 8.83 | ||
LU1330191385 | 783.74M | -1.17 | 7.47 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 8.97 | 745.4 | -0.73% | |
Tryg | DK0060636678 | 5.68 | 162.2 | +0.25% | |
Flutter Entertainment | IE00BWT6H894 | 5.25 | 21,830.0 | +1.16% | |
Bonesupport | SE0009858152 | 5.10 | 370.20 | +2.83% | |
AstraZeneca | GB0009895292 | 4.53 | 10,474.0 | 0.00% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review